ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGM
ANI Pharmaceuticals, Inc. (ANIP) posted $883.37M in revenue for fiscal 2025 (up 43.8% year over year), at a 8.7% net margin, and has compounded revenue about 33.5%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. has grown revenue from $128.62M to $883.37M over the last 10 fiscal years, compounding about 33.5% a year. The most recent year was up 43.8%, so growth is actually accelerating.
Net margin sits at 8.7%, up 12 points year over year. It carries about $291.84M of total debt.
At today's valuation the market is pricing in roughly -0.8% annual free-cash-flow growth — versus the 79.8% it actually delivered over the last five years, so the price is arguably undemanding against what it has already proven.
Synthesised from ANI Pharmaceuticals, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
ANI Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $128.62M | $176.84M | $201.58M | $206.55M | $208.47M | $216.14M | $316.38M | $486.82M | $614.38M | $883.37M |
| Gross profit | $79.84M | $97.81M | $128.55M | $143.39M | $121.32M | — | — | — | — | — |
| Net income | $3.93M | $-1.08M | $15.49M | $6.09M | $-22.55M | $-42.60M | $-49.52M | $17.15M | $-20.15M | $77.18M |
| Net margin | 3.1% | -0.6% | 7.7% | 3.0% | -10.8% | -19.7% | -15.7% | 3.5% | -3.3% | 8.7% |
Source: ANI Pharmaceuticals, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
ANI Pharmaceuticals, Inc.: no obvious red flags in the filings
Our deterministic scan of the filed statements — receivables vs sales, earnings vs cash, dilution, leverage and margins — didn't flag anything. Ask about the risks →
What growth is priced into ANIP stock?
At today's market cap of $1.85B, ANI Pharmaceuticals, Inc. is priced for free-cash-flow growth of about -0.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $171.39M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 79.8%/yr over the last five fiscal years and revenue 33.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of ANI Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ANIP in your portfolio →
ANI Pharmaceuticals, Inc. financial history by metric
Compare ANI Pharmaceuticals, Inc. with peers
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
ANI Pharmaceuticals, Inc. — frequently asked questions
What is ANI Pharmaceuticals, Inc.'s revenue?
ANI Pharmaceuticals, Inc. (ANIP) reported revenue of $883.37M for fiscal year 2025, up 43.8% from the prior year, according to its SEC filings.
Is ANI Pharmaceuticals, Inc. profitable?
Yes. ANIP earned net income of $77.18M in fiscal 2025, a net margin of 8.7%.
What is ANIP's P/E ratio?
ANI Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 20.8 based on the latest data in our nightly-refreshed cache.
How fast is ANI Pharmaceuticals, Inc. growing?
ANIP's revenue grew at roughly 33.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does ANI Pharmaceuticals, Inc. have?
As of fiscal year 2025, ANIP carried roughly $291.84M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is ANI Pharmaceuticals, Inc.'s market cap?
ANI Pharmaceuticals, Inc. (ANIP) has a market capitalization of about $1.85B, based on the latest data in our nightly-refreshed cache.
When does ANI Pharmaceuticals, Inc.'s fiscal year end?
ANIP's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ANIP stock?
At today's market cap of $1.85B, ANI Pharmaceuticals, Inc. is priced for free-cash-flow growth of about -0.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $171.39M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 79.8%/yr over the last five fiscal years and revenue 33.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from ANI Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.